Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Transaction

25 Mar 2021 09:14

RNS Number : 4793T
IXICO plc
25 March 2021
 

25 March 2021

 

IXICO plc

("IXICO" or the "Company")

 

Director/PDMR Dealing

 

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that Mark Warne, Non-Executive Director, today purchased 14,250 ordinary shares in the Company at an average price of 63 pence.

 

 

For further information please contact:

 

IXICO plc +44 20 3763 7499

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

Cenkos Securities plc (Nominated adviser and sole broker) +44 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

 

Walbrook PR Ltd

+44 (0)20 7933 8780

 

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

 

The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Mark Warne

2

Reason for notification

On market purchase

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

IXICO plc

b.

LEI

2138005M1F59O6HWSA97

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 1p each

ISIN: GB00BCLY7L40

 

b.

Nature of the transaction

 Purchase of ordinary shares

c.

Price(s) and volume(s)

Price(s) per share

Volume(s)

£0.66

250 shares

£0.64

1500 shares

£0.65

1500 shares

£0.63

1500 shares

£0.61

1500 shares

£0.61

1500 shares

£0.63

1500 shares

£0.62

5000 shares

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

14,250 shares

£0.63

e.

Date of the transaction

24 March 2021

f.

Place of the transaction

London Stock Exchange, AIM Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKELBLFXLBBBK
Date   Source Headline
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.